(FILE 'HOME' ENTERED AT 20:07:39 ON 24 APR 2003)

```
FILE 'CAPLUS' ENTERED AT 20:07:55 ON 24 APR 2003
            1137 S ISOQUERCITRIN OR 21637-25-2/RN
L1
              3 S L1 AND HERPE#
L2
             120 S HESPERITIN
L3
L4
              4 S L1 (5W) L3
            3322 S LUTEOLIN
L5
             541 S ACACETIN
L6
            1270 S OUERCITRIN
L7
           11957 S QUERCETIN
L8
             680 S L1 (5W) L8
L9
             314 S L7 (5W) L1
L10
              30 S L6 (5W) L1
L11
              30 S L6 (5W) L1
L12
              30 S L11 OR L12
L13
              29 S L13 NOT L4
L14
              16 S L9 AND ASCORB?
L15
               8 S L10 AND ASCORB?
L16
     FILE 'REGISTRY' ENTERED AT 21:16:01 ON 24 APR 2003
L17
               0 S 5-ETHYLDEOXYRIDINE/CN
                0 S 5-ETHYLDEOXYRIDINE
L18
               1 S 5-ETHYLDEOXYURIDINE
L19
L20
               1 S QUERCETIN/CN
             0 S GLANGIN/CN
1 S GALANGIN/CN
1 S KAEMPFEROL/CN
0 S PROPOLIS/CN
1 S CHRYSIN/CN
1 S APIGENIN/CN
1 S LUTEOLIN/CN
1 S ACACETIN/CN
1 S ERIODICTYOL/CN
1 S QUERCITRIN/CN
2 S CATECHOL/CN
1 S HESPERITIN/CN
               0 S GLANGIN/CN
L21
L22
L23
L24
L25
L26
L27
L28
L29
L30
L31
L32
               1 S HESPERITIN/CN
L33
               2 S ASCORBIC ACID/CN
     FILE 'CAPLUS, KOSMET, USPATFULL' ENTERED AT 21:18:15 ON 24 APR 2003
L34
           13819 S L20 OR QUERCETIN
L35
             776 S L22 OR GALANGIN
L36
            5904 S L23 OR KAEMPFEROL
L37
               0 S PROPOLIX
L38
            1610 S PROPOLIS
L39
            1356 S L25 OR CHRYSIN
L40
            4008 S L26 OR APIGENIN
L41
            3788 S L27 OR LUTEOLIN
L42
             764 S L28 OR ACACETIN
L43
             750 S L29 OR ERIODICTYOL
            2024 S L30 OR QUERCITRIN
L44
           56210 S L31 OR CATECHOL
L45
L46
             807 S L32 OR HESPERITIN
L47
          121486 S L33 OR ASCORBIC
L48
            356 S L19 OR ETHYLDEOXYURIDINE
              36 S L1 (30W) L32
L49
L50
             734 S L1 (30W) L34
L51
              26 S L1 (30W) L35
L52
             429 S L1 (30W) L36
```

```
L53
             3 S L1 (30W) L38
           45 S L1 (30W) L39
L54
          126 S L1 (30W) L40
L55
L56
           161 S L1 (30W) L41
            41 S L1 (30W) L42
L57
            34 S L1 (30W) L43
L58
L59
           455 S L1 (30W) (L44 OR L45 OR L46 OR L47 OR L48)
             4 S L49 AND (PHARMA? OR COSMET###)
L60
            62 S L50 AND (PHARM? OR COSMET?)
L61
             4 S L51 AND (PHARM? OR COSMET?)
L62
            41 S L52 AND (PHARM? OR COSMET?)
L63
             1 S L53 AND (PHARM? OR COSMET?)
L64
             8 S L54 AND (PHARM? OR COSMET?)
L65
             11 S L55 AND (PHARM? OR COSMET?)
L66
            23 S L56 AND (PHARM? OR COSMET?)
L67
            6 S L57 AND (PHARM? OR COSMET?)
6 S L58 AND (PHARM? OR COSMET?)
L68
L69
           59 S L59 AND (PHARM? OR COSMET?)
L70
          100 S L60 OR L61 OR L62 OR L63 OR L64 OR L65 OR L66 OR L67
L71
L72
           98 DUPLICATE REMOVE L71 (2 DUPLICATES REMOVED)
```

```
FILE 'CAPLUS' ENTERED AT 20:07:55 ON 24 APR 2003
       1137 S ISOQUERCITRIN OR 21637-25-2/RN
L2
            3 S L1 AND HERPE#
L3
           120 S HESPERITIN
            4 S L1 (5W) L3
L4
          3322 S LUTEOLIN
L5
L6
          541 S ACACETIN
L7
          1270 S OUERCITRIN
L8
         11957 S QUERCETIN
L9
           680 S L1 (5W) L8
           314 S L7 (5W) L1
L10
L11
            30 S L6 (5W) L1
            30 S L6 (5W) L1
L12
            30 S L11 OR L12
L13
L14
            29 S L13 NOT L4
L15
            16 S L9 AND ASCORB?
L16
            8 S L10 AND ASCORB?
    FILE 'REGISTRY' ENTERED AT 21:16:01 ON 24 APR 2003
            0 S 5-ETHYLDEOXYRIDINE/CN
L17
L18
             0 S 5-ETHYLDEOXYRIDINE
L19
             1 S 5-ETHYLDEOXYURIDINE
L20
             1 S QUERCETIN/CN
L21
             0 S GLANGIN/CN
L22
            1 S GALANGIN/CN
            1 S KAEMPFEROL/CN
L23
            0 S PROPOLIS/CN
L24
            1 S CHRYSIN/CN
L25
L26
            1 S APIGENIN/CN
L27
            1 S LUTEOLIN/CN
            1 S ACACETIN/CN
L28
            1 S ERIODICTYOL/CN
L29
            1 S QUERCITRIN/CN
L30
            2 S CATECHOL/CN
L31
            1 S HESPERITIN/CN
L32
```

2 S ASCORBIC ACID/CN

L33

ACCESSION NUMBER: 2000:117288 USPATFULL Pharmaceutical grade St. John's Wort TITLE: Khwaja, Tasneem A., Corona Del Mar, CA, United States INVENTOR(S): Friedman, Elliot P., Montecito, CA, United States PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA, United Statés (U.S. corporation) Pharmaprint Inc., Irvine, CA, United States (U.S. corporation) NUMBER KIND DATE _____ PATENT INFORMATION: US 6113907 20000905 US 1997-956602 19971023 (8) APPLICATION INFO.: Continuation-in-part of Ser. No. US 1997-838198, filed RELATED APPLN. INFO.: on 15 Apr 1997, now abandoned DOCUMENT TYPE: Utility FILE SEGMENT: Granted PRIMARY EXAMINER: Gitomer, Ralph LEGAL REPRESENTATIVE: Lyon & Lyon LLP NUMBER OF CLAIMS: 2 EXEMPLARY CLAIM: 1 NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s) LINE COUNT: 3067 CAS INDEXING IS AVAILABLE FOR THIS PATENT. . . . have shown that two of St. John's Wort's primary components, hypericin and pseudohypericin, inhibit a variety of encapsulated viruses, including herpes simplex (Weber et al., 1994) and the human immunodeficiency virus type 1 (HIV-1) virus associated with AIDS (Meruelo et al.,. . . . the aerial portion of the plant. These include the following DETD flavonols; kaempferol, luteolin, myricetin, quercetin (2%); flavone glycosides; quercitrin (0.524-0.3%), isoquercitrin [0.3%] (Dorossiev, 1985, Pharmazie 585-586; Koget, 1972, Khimiya Prirodnykh Soedinea 242-243), hyperin [0.7-1.1% hyperoside] (List and Horhammer, 1993), I3', II8-biapigenin. . in q % DETD Plant Part Constituent Concentration Total Flavonoids flowers 11.7 Total Flavonoids stems and leaves 7.4 Quercetin leaves and flowers 0.1-0.582 whole herb/flowers Quercitrin 0.524 - 0.3Isoquercitrin 0.3 Hyperin (hyperoside) 0.7 - 1.1I3, II8-biapigenin

I3, II8-biapigenin

stems and leaves

fresh flowers

non-detectable

0.1-0.5

0.01-0.05

(amentoflavone)

Rutin 0.095

Rutin 2

(Akhtardzhiev et al.,. .

DETD Three different mobile phases are used. To detect rutin, hyperoside and isoquercitrin, acetonitrile:water:phosphoric acid (16:83:1) is used with a run time of 30 minutes.

- DETD Standards for rutin, hyperoside, **isoquercitrin**, quercitrin and hypericin are available from Sigma, St. Louis, Mo., USA, with the rest available from Roth. The samples are. . .
- TT 56-12-2, GABA, biological studies 56-85-9, Glutamine, biological studies 56-86-0, Glutamic acid, biological studies 117-39-5, Quercitin 147-85-3, Proline, biological studies 153-18-4, Rutin 482-36-0, Hyperoside 522-12-3 548-04-9, Hypericin 1617-53-4, Amentoflavone 11079-53-1, Hyperforin

(bioassays for detn. of pharmaceutical grade St. John's wort materials from exts. and plant mixts.)

L72 ANSWER 85 OF 98 USPATFULL

ACCESSION NUMBER: 86:57928 USPATFULL

TITLE: Flavonoid phosphate salts of aminoglycoside

antibiotics

Wahliq, Helmut, Darmstadt, Germany, Federal Republic INVENTOR(S):

of

Dingeldein, Elvira, Dreieich, Germany, Federal

Republic

of

Kirchlechner, Richard, Rott a. Inn, Germany, Federal

Republic of

Orth, Dieter, Darmstadt, Germany, Federal Republic of Rogalski, Werner, Alsbach, Germany, Federal Republic

of

PATENT ASSIGNEE(S): Merck Patent Gesellschaft mit beschraenkter Haftung,

Darmstadt, Germany, Federal Republic of (non-U.S.

corporation)

NUMBER KIND DATE _____ 19861014

PATENT INFORMATION:

APPLICATION INFO.:

US 1984-613131 19840523

RELATED APPLN. INFO.:

Continuation-in-part of Ser. No. US 1982-377779, filed

on 13 May 1982, now abandoned

NUMBER DATE -----DE 1981-3118856 19810513

PRIORITY INFORMATION:

DE 1982-3206725 19820225

DOCUMENT TYPE: FILE SEGMENT:

Utility Granted

PRIMARY EXAMINER: ASSISTANT EXAMINER:

Brown, Johnnie R. Peselev, Elli

LEGAL REPRESENTATIVE:

Millen & White

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

12 1,11

LINE COUNT:

528

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Flavonoid phosphates of aminoglycoside antibiotics are useful sparingly

soluble salts, e.g., for achieving a depot effect.

SUMM . . . nicotiflorin (caempferol 3-rutinoside), lespedin (caempferol 3,7-dirhamnoside), robinin (caempferol 3-robinoside 7-rhamnoside

L72 ANSWER 84 OF 98 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1987:483739 CAPLUS

DOCUMENT NUMBER: 107:83739

TITLE: Linden blossoms. Isoquercitrin: major

flavone of the pharmacopeial drug

AUTHOR(S): Wichtl, Max; Bozek, Barbara; Fingerhut, Thomas

CORPORATE SOURCE: Inst. Pharm. Biol., Philipps-Univ., Marburg, 3550,

Fed. Rep. Ger.

SOURCE: Deutsche Apotheker Zeitung (1987), 127(10), 509-510

CODEN: DAZEA2; ISSN: 0011-9857

DOCUMENT TYPE: Journal LANGUAGE: German

AB Isoquercitrin (quercetin 3-glucoside) (I) was identified as the major flavone from the linden blossoms of German Pharmacopeia 9. This finding corrects the work, described in the German Pharmacopeia 8, that hyperoside is the main flavone.

TI Linden blossoms. **Isoquercitrin**: major flavone of the **pharmacopeial** drug

AB Isoquercitrin (quercetin 3-glucoside) (I) was identified as the major flavone from the linden blossoms of German Pharmacopeia 9. This finding corrects the work, described in the German Pharmacopeia 8, that hyperoside is the main flavone.

ST isoquercitrin linden blossom

IT Linden

(isoquercitrin of blossoms of, German pharmacopeia in relation to)

IT 21637-25-2, Isoquercitrin RL: BIOL (Biological study)

L72 ANSWER 75 OF 98 CAPLUS COPYRIGHT 2003 ACS

1993:240541 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER:

118:240541

TITLE:

Pharmacognostic study on Euphorbia

ebracteolata. (I). Flavonoid constituents

AUTHOR (S):

Lee, Sang Cheol; Ahn, Beung Tae; Park, Woong Yang; Lee, Seung Ho; Ro, Jai Seup; Lee, Kyong Soon; Ryu,

Eung Kul

CORPORATE SOURCE:

Coll. Pharm., Chungbuk Natl. Univ., Cheongju,

360-763,

S. Korea

SOURCE:

Saengyak Hakhoechi (1992), 23(3), 126-31

CODEN: SYHJAM; ISSN: 0253-3073

DOCUMENT TYPE:

Journal Korean

LANGUAGE:

AB

Four flavonoids were isolated from the aerial parts of E. ebracteolata. On the basis of chem. and spectroscopic evidence, the structures of these compds. were established as isoquercitrin, rutin,

kaempferol 3-0-rutinoside and quercetin

3-O-(2''-O-galloyl)-.beta.-D-glucoside which was the main flavonoid component in this plant. This is the first example of isolation of flavonoids from E. ebracteolata.

- Pharmacognostic study on Euphorbia ebracteolata. (I). Flavonoid TI constituents
- Four flavonoids were isolated from the aerial parts of E. ebracteolata. AB On the basis of chem. and spectroscopic evidence, the structures of these compds. were established as isoquercitrin, rutin, kaempferol 3-0-rutinoside and quercetin

- 3-O-(2''-O-galloyl)-.beta.-D-glucoside which was the main flavonoid component in this plant. This is the first example of isolation of flavonoids from E. ebracteolata.
- 153-18-4, Rutin 17650-84-9, Kaempferol 3-0-rutinoside 21637-25-2, Isoquercitrin 69624-79-9

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)

(of Euphorbia ebracteolata)

ATFULL

ACCESSION NUMBER:

1999:167038 USPATFULL

TITLE:

Flavonoid and biflavonoid derivatives, their pharmaceutical compositions, their anxiolytic

activity

INVENTOR(S):

Cassels, Bruce Kennedy, Casilla, Chile Dajas, Federico Jose, Montevideo, Uruguay Medina, Jorge Horacio, Buenos Aires, Argentina Paladini, Alejandro Constantino, Buenos Aires,

Argentina

Silveira, Rodolfo Horacio, Montevideo, Uruguay

PATENT ASSIGNEE(S):

University of Strathclyde, United Kingdom (non-U.S.

corporation)

KIND DATE NUMBER _____

PATENT INFORMATION:

US 6004998

19991221

APPLICATION INFO.:

19970929 (8)

RELATED APPLN. INFO.:

US 1997-939975

Division of Ser. No. US 586796

NUMBER DATE -----

PRIORITY INFORMATION:

GB 1993-17071 19930817

DOCUMENT TYPE:

Utility Granted

FILE SEGMENT: PRIMARY EXAMINER:

Stockton, Laura L.

LEGAL REPRESENTATIVE:

Alston & Bird LLP

NUMBER OF CLAIMS:

EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

19 Drawing Figure(s); 19 Drawing Page(s)

LINE COUNT:

637

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Certain flavonoids, notably derivatives of flavone, chrysin and apigenin, together with dimers thereof such as amentoflavone, have been

found to possess anxiolytic properties (i.e., anxiety reducing

properties) without exhibiting a sedative effect. Novel compounds and

cerebral function

of mammals including human to improve the memory and cerebral function and

capable of treating or ameliorating cerebral and neurologic diseases such as

senile dementia and Parkinson's disease without causing side effect. The agent

can be prepared by compounding a substance having superoxide dismutase(SOD)-like activity and/or antioxidation activity (including scavenger

function) (e.g. fat-soluble ascorbic acid), a phenolic compound such as

guaiacol, phenol, eugenol phenylethanol, a glycoprotein such as asparatin,

orientin (lutexin), cisorientin (lutonaletin), isoquercitin and rutin and a

sugar compound such as saccharified flavonoid.

COPYRIGHT: (C)1994,JPO&Japio

04/25/2003, EAST Version: 1.03.0002

L2 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 1992:630163 CAPLUS

DOCUMENT NUMBER: 117:230163

TITLE: Isolation and characterization of an antiviral

flavonoid from Waldsteinia fragarioides Abou-Karam, Mohamed; Shier, W. Thomas

AUTHOR(S): Abou-Karam, Mohamed; Shier, W. Thomas CORPORATE SOURCE: Coll. Pharm., Univ. Minnesota, Minneapolis, MN,

55455,

USA

SOURCE: Journal of Natural Products (1992), 55(10), 1525-7

CODEN: JNPRDF; ISSN: 0163-3864

DOCUMENT TYPE: J

Journal English

LANGUAGE: English

AB The antiviral agent in a fraction

AB The antiviral agent in a fraction from Waldsteinia fragarioides (Rosaceae)

was purified using bioassay-guided fractionation of activity against herpes simplex type 1 virus. Structural elucidation by instrumental methods identified the active component to be the known

instrumental methods identified the active component to be the known flavonoid glycoside, **isoquercitrin** (3,3',4',5,7-

pentahydroxyflavone-3.beta.-O-glucoside), which had not previously been shown to possess antiviral activity.

AB The antiviral agent in a fraction from Waldsteinia fragarioides (Rosaceae)

was purified using bioassay-guided fractionation of activity against herpes simplex type 1 virus. Structural elucidation by instrumental methods identified the active component to be the known flavonoid glycoside, isoquercitrin (3,3',4',5,7-pentahydroxyflavone-3.beta.-O-glucoside), which had not previously been shown to possess antiviral activity.

ST Waldsteinia isoquercitrin antiviral

IT Waldsteinia fragarioides

(isoquercitrin from, isolation and antiviral activity of)

IT Virucides and Virustats

(isoquercitrin, from Waldsteinia fragarioides)

IT 21637-25-2, Isoquercitrin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BIOL (Biological study)

(from Waldsteinia fragarioides, isolation and structure and antiviral activity of)

TITLE: Effects of extracts of Zanthoxylum fruit and their

constituents on spontaneous beating rate of

myocardial

cell sheets in culture

AUTHOR(S): Huang, Xin Li; Kakiuchi, Nobuko; Che, Qing Ming;

Huang, Sheng Lun; Hattori, Masao; Namba, Tsuneo

CORPORATE SOURCE: Res. Inst. Wakan-Yaku, Toyama Med. Pharm. Univ.,

Toyama, 930-01, Japan

SOURCE: Phytother. Res. (1993), 7(1), 41-8

CODEN: PHYREH; ISSN: 0951-418X

DOCUMENT TYPE: Journal LANGUAGE: English

AB In the course of our studies on naturally occurring cardioactive agents, we investigated the effects of water and methanol exts. of a Chinese

crude

drug Huajiao (the dried fruit of Zanthoxylum bungeanum) on the

spontaneous

beating rate (BR) of embryonic mouse myocardial cell sheets in culture.

Both exts. significantly increased the BR. Through bioassay directed
fractionation of the exts., hydroxy-.beta.-sanshool, xanthoxylin and two

quercetin glycosides, hyperin and quercitrin, were found to increase the BR in a std. medium (2.1 mM Ca2+). In a low Ca2+ medium (0.5 mM Ca2+), these compds. suppressed the decrease of BR, which was induced by low

Ca2+. Of 16 flavonoids related in structure to hyperin (4) and quercitrin

(6), quercetin, isoquercitrin, rutin, myricetin and

myricitrin also increased the BR in the std. medium, while kaempferol and luteorin decreased the BR in the std. medium. When compared with control,

hydroxy-.beta.-sanshool and xanthoxylin stimulated 13-15 fold calcium uptake of the cultured myocardial cells, which might have caused the poschronotropic effect. Hyperin and quercitrin did not affect calcium uptake

of the myocardial cells, Na+-K+ ATPase activity or Ca2+-ATPase activity of

sarcoplasmic reticulum.

L18 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1987:483739 CAPLUS

DOCUMENT NUMBER: 107:83739

TITLE: Linden blossoms. Isoquercitrin: major flavone of the

pharmacopeial drug

AUTHOR(S): Wichtl, Max; Bozek, Barbara; Fingerhut, Thomas CORPORATE SOURCE: Inst. Pharm. Biol., Philipps-Univ., Marburg, 3550,

Fed. Rep. Ger.

SOURCE: Dtsch. Apoth. Ztg. (1987), 127(10), 509-510

CODEN: DAZEA2; ISSN: 0011-9857

DOCUMENT TYPE: Journal

LANGUAGE: German

AB Isoquercitrin (quercetin 3-glucoside) (I) was

identified as the major flavone from the linden blossoms of German Pharmacopeia 9. This finding corrects the work, described in the German Pharmacopeia 8, that hyperoside is the main flavone.

L18 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1985:12244 CAPLUS

DOCUMENT NUMBER: 102:12244

.TITLE: Studies on the constituents of Lindera species (I).

On

the flavonoid compounds of Lindera families

L72 ANSWER 87 OF 98 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1985:583618 CAPLUS

DOCUMENT NUMBER: 103:183618

Thin-layer chromatography in the pharmacy. TITLE:

Examples of usage

AUTHOR (S): Pachaly, Peter

Pharm. Inst., Univ. Bonn, Bonn, 5300/1, Fed. Rep. CORPORATE SOURCE:

Ger.

Deutsche Apotheker Zeitung (1985), 125(24), 1223-32 SOURCE:

CODEN: DAZEA2; ISSN: 0011-9857

DOCUMENT TYPE: Journal LANGUAGE: German

TLC for helping pharmacists to identify drugs and medicinal AB plants is described. Identification of vitamins A, E and D derivs., salicylates, flavonoids, glycosides, carboxylic acids, and other compds. in blackberry, raspberry, and Primula officinalis flowers is described. Actual chromatograms of all these compds. are given which aid the interpretation of results. Spray reagents, mobile phases and detection methods are given.

Thin-layer chromatography in the pharmacy. Examples of usage TΙ

TLC for helping pharmacists to identify drugs and medicinal AB plants is described. Identification of vitamins A, E and D derivs., salicylates, flavonoids, glycosides, carboxylic acids, and other compds. in blackberry, raspberry, and Primula officinalis flowers is described. Actual chromatograms of all these compds. are given which aid the interpretation of results. Spray reagents, mobile phases and detection methods are given.

TLC pharmaceutical chemist; plant medicinal TLC; chromatog thin STlayer pharmaceutical

ΙT Pharmaceutical analysis

(TLC in)

50-78-2 **50-81-7**, analysis 58-95-7 65-45-2 67-97-0 69-72-7, analysis 77-92-9, analysis 79-81-2 91-64-5 **117-39-5** 127-47-9 149-91-7, analysis 119-36-8 153-18

ACS

ACCESSION NUMBER:

1989:88626 CAPLUS

DOCUMENT NUMBER:

110:88626

TITLE:

Immunosuppressants containing flavonoids

INVENTOR(S):

Suzuki, Kazuo; Hosokawa, Tomohide

PATENT ASSIGNEE(S):

Cosmo Kaihatsu K. K., Japan

SOURCE:

Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63233917	A2	19880929	JP 1987-67798	19870324
JP 2544734	В2	19961016		

PRIORITY APPLN. INFO.:

JP 1987-67798 19870324

OTHER SOURCE(S):

MARPAT 110:88626

AB Immunosuppressants contg. flavonoids I (R1-R9 = H, OH, OMe) or their glycosides, useful in organ transplantations, are described. Myricetin showed 10.5% and 65.2% 51Cr release at 9.1 .mu.g/mL and 0 .mu.g/mL, resp.,

in a 51Cr release test using allogeneic killer T-cells and mice spleen cells.

90-18-6, Quercetagetin 90-19-7, Rhamnetin TΤ 117-39-5, Quercetin 153-18-4, Rutin 480-15-9, Datiscetin??? 480-16-0, Morin 480-19-3, Isorhamnetin 480-40-0, Chrysin??? 480-44-4, Acacetin 482-34-8, Hibiscitrin??? 490-31-3, Robinetin??? 491-54-3, Kaempferid??? 520-18-3, Kaempferol 520-27-4, Diosmin??? 520-36-5, Apigenin 525-82-6, Flavone 527-95-7, 528-48-3 529-44-2, Myricetin 529-53-3, Scutellarein Diosmetin??? Herbacetin 552-54-5, Rhamnazin??? 577-24-2, Hibiscetin??? 578-74-5, Cosmosiin??? 604-80-8, Narcissin??? 1329-10-8, Toringin??? 16310-92-2, Datiscin??? 17912-87-7, Myricitrin??? 21637-25-2, Isoquercitrin 28288-98-4, Dactilin??? 32427-55-7, Tambuletin??? RL: BIOL (Biological study) (immunosuppressant)

L14 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:

1995:341162 CAPLUS

DOCUMENT NUMBER:

122:142563

TITLE:

Pharmaceutical compositions containing flavonoids as

chondroprotective agents

INVENTOR(S):
PATENT ASSIGNEE(S):

Watanabe, Koju; Niimura, Koichi; Umekawa, Kiyonori

Kureha Chemical Industry Co., Ltd., Japan

SOURCE:

Eur. Pat. Appl., 10 pp.

DOCUMENT TYPE:

CODEN: EPXXDW Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PAT	TENT NO.	KIND	DATE	APPLICATION NO.	DATE
	633022		19950111	EP 1994-109872	19940627
EΡ	633022	A3	19950802		
EΡ	633022	B1	19970219		
	R: CH, DE,	FR, GB	, IT, LI, SE		
JР	07025761	Δ2	19950127	TP 1993-194182	19930709



```
CA 2126513
                      AA
                           19950110
                                          CA 1994-2126513 19940622
     EP 719554
                      A1 19960703
                                          EP 1996-103715
                                                            19940627
        R: CH, DE, FR, GB, IT, LI, SE
                     A1
                          19950119
                                          AU 1994-67339
                                                           19940707
                      B2
                           19950518
     AU 659579
     CN 1100633
                      Α
                            19950329
                                          CN 1994-108234
                                                           19940708
     US 5650433
                      Α
                           19970722
                                          US 1995-519179
                                                           19950825
PRIORITY APPLN. INFO.:
                                        JP 1993-194182
                                                           19930709
                                       EP 1994-109872
                                                           19940627
                                        US 1994-271951
                                                           19940708
OTHER SOURCE(S):
                        MARPAT 122:142563
     Pharmaceutical compns. contg. flavonoids as chondroprotective agents are
     prepd. The above compds. strongly inhibit proteoglycan depletion from
the
     chondrocyte matrix and exhibit a function to protect cartilage, and thus,
     are extremely effective for the treatment of arthropathy. The amt. of
     glycosaminoglycans (major constituent of proteoglycans) in cultured
     chondrocytes in presence of 0.1.mu.g/mL phorbol myristate acetate and 100
     .mu.M apigenin (I) was 33.3 as compared with 16.5 .mu.g/mL for controls
     contg. no I. Pharmaceutical granules contained I 20, lactose 68, and
    hydroxypropyl cellulose 12 parts.
     50-99-7D, GLucose, compds. with flavonoids 57-48-7D, Fructose, compds.
TТ
    with flavonoids 58-86-6D, Xylose, compds. with flavonoids
                                                                 59-23-4D,
    Galactose, compds. with flavonoids 90-18-6, Quercetagetin
                                                                  90-19-7,
               90-74-4D, Rutinose, compds. with flavonoids 117-39-5,
     Rhamnetin
                147-81-9D, Arabinose, compds. with flavonoids 153-18-4,
     Quercetin
     Rutin 301-19-9, Robinin 480-10-4, Astragalin 480-15-9, Datiscetin
     480-16-0, Morin 480-18-2, Taxifolin 480-19-3, Isorhamnetin
480-20-6,
    Aromadendrin 480-35-3, Eriodictin 480-36-4, Linarin
                                                               480-39-7,
     Pinocembrin 480-40-0, Chrysin 480-41-1, Naringenin
                                                              480-44-4,
     Acacetin 482-38-2, Kaempferitrin 491-67-8, Baicalein
     491-70-3, Luteolin 520-18-3, Kaempferol 520-26-3 520-27-4, Diosmin
              520-34-3, Diosmetin 520-36-5, Apigenin
     520-33-2
                                                           522-12-3,
Quercitrin
     525-82-6, Flavone 528-48-3, Fisetin 529-39-5, Sakuranin
    Myricetin 529-55-5, Prunin 548-58-3, Primetin 548-75-4,
     Quercetagitrin 548-82-3, Pinobanksin 552-58-9, Eriodictyol
     552-74-9D, Robinobiose, compds. with flavonoids 572-31-6, Engelitin
    578-74-5, Cosmosiin 1329-10-8, Toringin 2957-21-3, Sakuranetin 3615-41-6D, Rhamnose, compds. with flavonoids 5373-11-5, Glucolut
                                                    5373-11-5, Glucoluteolin
     10236-47-2, Naringin 17912-87-7, Myricitrin
                                                     20344-46-1, Galuteolin
     20725-03-5, Fustin 21637-25-2, Isoquercitrin
     23627-87-4, Trifolin 26544-34-3, Apiin
                                              27200-12-0, Ampelopsin
     28757-27-9, Salipurpin 29838-67-3, Astilbin 139759-42-5D, compds.
with
     flavonoids
     RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
     study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
     (Uses)
```

(pharmaceutical compns. contg. flavonoids as chondroprotective agents)

US 5650433 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS L41999:764378 CAPLUS AN DN 131:355899 Flavonoid compounds and their use, especially in cosmetics TI Bresson-Rival, Delphine; Mariotte, Anne-Marie; Boumendjel, Ahcene; IN Perrier, Eric Coletica S. A., Fr. PΑ Ger. Offen., 22 pp. SO CODEN: GWXXBX DTPatent German LA FAN.CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE ----**-**--------------DE 1999-19922287 19990514 DE 19922287 19991125 PΙ A1 FR 2778663 19991119 FR 1998-6194 19980515 A1 FR 2778663 20010518 В1 US 6235294 B1 20010522 US 1998-113158 19980710 JP 1999-136331 19990517 JP 2000026263 **A2** 20000125 US 2001-828986 US 2001031735 20011018 20010410 Α1 US 6471973 B2 20021029 19980515 PRAI FR 1998-6194 Α

19980710

Α3

US 1998-113158

MARPAT 131:355899

os

L72 ANSWER 97 OF 98 CAPLUS COPYRIGHT 2003 ACS

1970:30225 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 72:30225

TITLE: New antidyspeptic agent in hepatic-biliary

> disturbances Copelman, Helio

AUTHOR (S): CORPORATE SOURCE:

Hosp. IASEG, Brazil

SOURCE:

Hospital (Rio de Janeiro) (1969), 75(4), 1463-8

CODEN: HOSOA3; ISSN: 0018-5469

DOCUMENT TYPE:

Journal

LANGUAGE: Portuguese

AB A substance extd. from Tilia alburnum had the following compn.: quercetin, quercitrin, isoquercitrin,

quercetin-3-glucoside, quercetin-7-rhamnoside,

kaempherol, kaempheritrin, astragalin, rutin (0.05%), and tiliadin

(0.31%). Pharmacol. characteristics and clin. results of the treatment of dyspeptic syndromes with this ext. were discussed.

AB A substance extd. from Tilia alburnum had the following compn.:

quercetin, quercitrin, isoquercitrin,

quercetin-3-glucoside, quercetin-7-rhamnoside,

kaempherol, kaempheritrin, astragalin, rutin (0.05%), and tiliadin (0.31%). Pharmacol. characteristics and clin. results of the

treatment of dyspeptic syndromes with this ext. were discussed.

117-39-5 153-18-4 480-10-4 482-35-9 **520-18-3** IT

16290-08-7 18016-58-5 25242-92-6 522-12-3

L72 ANSWER 37 OF 98 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:9203 CAPLUS

DOCUMENT NUMBER: 134:197925

TITLE: Chemical and pharmacological evaluation of

Hypericum perforatum extracts

AUTHOR(S): Sloley, B. Duff; Urichuk, Liana J.; Ling, Lei; Gu,

Lie-Dong; Coutts, Ronald T.; Pang, Peter K. T.; Shan,

Jacqueline J.

CORPORATE SOURCE: CV Technologies, Edmonton Research Park, Edmonton,

AB,

T6N 1E5, Can.

SOURCE: Acta Pharmacologica Sinica (2000), 21(12), 1145-1152

CODEN: APSCG5

PUBLISHER: Science Press

DOCUMENT TYPE: Journal LANGUAGE: English

AB The concns. of chem. components in the exts. of leaves and flowers of H. perforatum (St. John's wort) in a no. of selected samples were evaluated after chem. characterization, and the effects of these exts. on several pharmacol. properties including effects of the exts. on inhibition of 5-hydroxytryptamine (5-HT) uptake and on antioxidant properties were detd. METHODS: The samples were analyzed for the presence of characteristic components by HPLC directly coupled to a UV detector and a pos. or neg. mode electrospray-mass spectrometric detector. The effects of exts. on 5-HT uptake were detd. by quantifying 3H-5-HT incorporation into rat hippocampal prisms. Ests. of effects of exts. on free radical scavenging capacity were made using a dynamic assay based on the ability of compds. to prevent the initiation of a colored reaction produced by

the

horseradish peroxidase-catalyzed formation of hydroxyl free radicals from hydrogen peroxide using 2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) as the color indicator. RESULTS: The chem. profile of a no. of exts. were detd. and found to differ substantially from each other. Inhibition of 5-HT uptake was found to correlate with hyperforin content and free radical scavenging capacity was found to correlate with the content of several flavonoids including quercetin and hyperoside. CONCLUSION: Standardized exts. of H perforatum varied substantially in the concn. of several characteristic chems. The correlation between pharmacol. activity and certain characteristic chems. found in these exts. indicates that the medicinal benefit derived from selected exts. will vary considerably depending on their chem. compn.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILA

L72 ANSWER 26 OF 98 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:152264 CAPLUS

DOCUMENT NUMBER: 134:197877

TITLE: Additive for improving the water resistance of

cosmetic or dermatological formulations

INVENTOR(S):
Vollhardt, Jurgen

PATENT ASSIGNEE(S): Dragoco Gerberding & Co Aktiengesellschaft, Germany

SOURCE: Eur. Pat. Appl., 13 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO. DATE			
	-				
EP 1078638	A1 20010228	EP 2000-116508 20000731			
R: AT, BE,	CH, DE, DK, ES,	FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
IE, SI,	LT, LV, FI, RO				
US 6274124	B1 20010814	US 1999-378402 19990820			
JP 2001072531		JP 2000-240160 20000808			
BR 2000003897	A 20010403	BR 2000-3897 20000817			
PRIORITY APPLN. INFO.: US 1999-378402 A 19990820					
AB Disclosed is a method for imparting water resistance to or improving					
water					

resistance of a **cosmetic** or dermatol. formulation, comprising adding an water resistance enhancing effective amt. of 1,2-pentanediol to the otherwise conventional **cosmetic** or dermatol. formulation comprising at least one **cosmetic** and/or dermatol. active agent in a **cosmetically** and/or **pharmaceutically** acceptable carrier for topical application to the skin of humans. A sunscreen formulation contg. sodium dihydroxycetyl phosphate 3, bisabolol 0.1, octyl

octanoate 5, caprylic/capric triglyceride 10, 3-(4-methylbenzyliden)-camphor 4, Bu methoxydibenzoylmethane 2, octyl-triazone 4, octyl-methoxycinnamate 4, a mixt. of titanium diox

```
FILE 'CAPLUS' ENTERED AT 20:07:55 ON 24 APR 2003
          1137 S ISOQUERCITRIN OR 21637-25-2/RN
L1
L2
            3 S L1 AND HERPE#
L3
           120 S HESPERITIN
            4 S L1 (5W) L3
L4
L5
          3322 S LUTEOLIN
           541 S ACACETIN
L6
L7
          1270 S QUERCITRIN
         11957 S QUERCETIN
L8
L9
           680 S L1 (5W) L8
L10
           314 S L7 (5W) L1
            30 S L6 (5W) L1
L11
            30 S L6 (5W) L1
L12
            30 S L11 OR L12
L13
            29 S L13 NOT L4
L14
           16 S L9 AND ASCORB?
L15
L16
            8 S L10 AND ASCORB?
```